Thyroglobulin measurement in differentiated thyroid carcinoma management

References

• Schlumberger M. Medical progress: papillary and follicular thyroid carcinoma. N. Engl. J. Med.338, 297–306 (1998).
   PubMed Web of Science ®Google Scholar
• Klain M, Richard M, Leboulleux S et al. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur. J. Nucl. Med.29(Suppl. 2), S479–S485 (2002).
   Google Scholar
• Pacini F. Follow-up of differentiate thyroid cancer. Eur. J. Nucl. Med.29(Suppl. 2), 492–496 (2002).
   Google Scholar
• Schlumberger M, Berg G, Cohen O et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur. J. Endocrinol.150, 105–112 (2004).
   PubMed Web of Science ®Google Scholar
• Kohno Y, Tarutani O, Sakata S, Kakajima H. Monoclonal antibodies to thyroglobulin elucidate differences in protein structure of thyroglobulin in healthy individuals and those with papillary adenocarcinoma. J. Clin. Endocrinol. Metab.61, 343–350 (1985).
   PubMed Web of Science ®Google Scholar
• Hufner M, Pfahl H, Bethauser H, Heilig B, Georgi P. Comparative plasma thyroglobulin measurements with three non-cross-reactive monoclonal antibodies in metastatic thyroid cancer patients. Acta Endocrinologica118, 528–532 (1988).
   PubMedGoogle Scholar
• Feldt-Rasmussen U, Profilis C, Colinet E et al. Human thyroglobulin reference material (CRM 457). 1st part: assessment of homogeneity, stability and immunoreactivity. Ann. Biol. Clin.54, 337–342 (1996).
   PubMed Web of Science ®Google Scholar
• Baloch Z, Carayon P, Conte-Devolx B et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.Thyroid13, 123–126 (2003).
   Google Scholar
• Persoon ACM, Links TP, Wilde J et al. Potential contributory value of thyroglobulin (Tg) recovery testing to quantitative Tg antibody measurement in determining serum Tg measurement interference in differentiated thyroid carcinoma. Clin. Chem.52, 1196–1199 (2006).
   PubMedGoogle Scholar
• Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain autoantibodies. Clin. Chem.43, 413–415 (1997).
   PubMedGoogle Scholar
• Giovanella L, Ceriani L, Keller F. How thyroglobulin recovery test really adds to anti-thyroglobulin antibodies quantitative assay when serum thyroglobulin is employed to manage differentiated thyroid carcinoma? Clin. Chem.52, 1196–1199 (2006).
   PubMedGoogle Scholar
• Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab.90, 5566–5575 (2005).
   PubMed Web of Science ®Google Scholar
• Preissner CM, O’Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assay. J. Clin. Endocrinol. Metab.88, 3069–3074 (2003).
   PubMed Web of Science ®Google Scholar
• Giovanella L, Ghelfo A. Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma. Clin. Chem.53, 1871–1872 (2007).
   PubMed Web of Science ®Google Scholar
• Weigel RJ, McDougall IR. The role of radioactive iodine in the treatment of well-differentiated thyroid cancer. Surg. Oncol. Clin. North Am.1, 625–638 (2006).
   Google Scholar
• Torrens JI, Burch HB. Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol. Metab. Clin. North Am.30, 429–467 (2001).
   PubMed Web of Science ®Google Scholar
• Guarino E, Tarantini B, Pilli T et al. Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer. Thyroid15, 1041–1045 (2005).
   PubMedGoogle Scholar
• Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin. Endocrinology67, 547–551 (2007).
   PubMedGoogle Scholar
• Westbury C, Vini L, Fisher C, Harmer C. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid10, 171–176 (2000).
   PubMedGoogle Scholar
• Ronga G, Filesi M, Ventroni G et al. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastasis from differentiated thyroid carcinoma. Eur. J. Nucl. Med.26, 1448–1452 (1999).
   PubMedGoogle Scholar
• Grünwald F, Menzel C, Fimmers R et al. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J. Nucl. Med.37, 1962–1964 (1996).
   PubMedGoogle Scholar
• Makarewicz J, Adamczewski Z, Knapska-Kucharska M, Lewinski A. Evaluation of the diagnostic value of first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery. Exp. Clin. Endocrinol. Diabetes114, 485–489 (2006).
   PubMed Web of Science ®Google Scholar
• Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin. Chem. Lab. Med.43, 843–847 (2005).
   PubMedGoogle Scholar
• Pacini F, Ladenson PW, Schlumberger M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab.91, 926–932 (2006).
   PubMed Web of Science ®Google Scholar
• Taieb D, Lussato D, Guedj E, Roux F, Mundler O. Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy. Thyroid16, 177–179 (2006).
   PubMedGoogle Scholar
• Giovanella L, Ceriani L. Is the thyroglobulin measurement under thyroxine of prognostic value before rhTSH-aided radioiodine ablation in differentiated thyroid carcinoma? Eur. J. Nucl. Med. Mol. Imaging34(Suppl. 2), S230 (2007)
   Google Scholar
• Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer97, 90–96 (2003).
   PubMed Web of Science ®Google Scholar
• Cailleaux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J. Clin. Endocrinol. Metab.85, 175–178 (2000).
   PubMedGoogle Scholar
• Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid carcinoma without diagnostic (131)I scanning. J. Clin. Endocrinol. Metab.87, 1486–1489 (2002).
   PubMedGoogle Scholar
• Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid carcinoma: new paradigms using recombinant human thyrotropin. Endocr. Relat. Cancer9, 227–247 (2002).
   PubMed Web of Science ®Google Scholar
• Mazzaferri E, Robbins RJ, Spencer CA et al. A consensus report of the role of serum thyroglobulin as a monitorino method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.88, 1433–1441 (2003).
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol.154, 787–803 (2006).
   PubMed Web of Science ®Google Scholar
• Rosario PW, Borges MA, Fagundes TA, Franco AC, Purisch S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin. Endocrinol.62, 121–125 (2005).
   PubMedGoogle Scholar
• Persoon AC, Jager PL, Sluiter WJ, Plukker JT, Wolffenbuttel BH, Links TP. A sensitive Tg assay or rhTSH stimulated Tg: what’s the best in the long-term follow-up of patients with differentiated thyroid carcinoma? PLoS ONE2(8), e816 (2007).
   Google Scholar
• Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F, Spiano G. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant thyrotropin-stimulated assay and inaging procedures. Clin. Chem. Lab. Med.44, 648–652 (2006).
   PubMedGoogle Scholar
• Smallridge RC, Meek S, Morgan MA et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J. Clin. Endocrinol. Metab.92, 82–87 (2007).
   PubMed Web of Science ®Google Scholar
• Iervasi A, Iervasi G, Ferdeghini M et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin. Endocrinol.67, 434–441 (2007).
   PubMedGoogle Scholar
• Schlumberger M, Hitzel A, Toubert ME et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J. Clin. Endocrinol. Metab.92, 2487–2495 (2007).
   PubMed Web of Science ®Google Scholar
• Mc Dougall IR. 131I treatment of 131I negative whole body scans, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid7, 669–672 (1997).
   PubMedGoogle Scholar
• Heemstra KA, Lyu YY, Stokkel M et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin. Endocrinol.66, 58–64 (2007).
   PubMed Web of Science ®Google Scholar
• Zophel K, Wünderlich G, Smith BR. Serum thyroglobulin measurements with high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid13, 861–865 (2003).
   PubMed Web of Science ®Google Scholar
• Zanotti-Fregonara P, Khoury A, Duron F et al. Which thyroid cancer patients need periodic stimulation tests? Eur. J. Nucl. Med. Mol. Imaging34, 541–546 (2007).
   PubMedGoogle Scholar
• Castagna MG, Brilli L, Pilli T et al. Limited value of repeat recombinant thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J. Clin. Endocrinol. Metab.93(1), 76–81 (2008).
   PubMed Web of Science ®Google Scholar
• Shammas A, Degirmenci B, Mountz JM et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J. Nucl. Med.48, 221–226 (2007).
   PubMedGoogle Scholar
• Zoller M, Kohlfuerst S, Igerc I et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur. J. Nucl. Med. Mol. Imaging34, 487–495 (2007).
   PubMedGoogle Scholar
• Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur. J. Endocrinol.138, 249–252 (1998).
   PubMedGoogle Scholar
• Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid14, 959–963 (2004).
   PubMed Web of Science ®Google Scholar
• Snozek CH, Chambers EP, Reading C et al. Serum thyroglobulin, high resolution ultrasound and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J. Clin. Endocrinol. Metab.92, 4278–4281 (2007).
   PubMed Web of Science ®Google Scholar